Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with potential diagnosis of ovarian, fallopian, or primary peritoneal cancer.~2. Care plan including surgical debulking and traditional adjuvant or neo-adjuvant chemotherapy (6-9 cycles of platinum and taxane based therapy).~3. Eastern Cooperative Oncology Group performance status 0-2.~4. Age \> 18 years or \< 80 years.~5. Adequate renal function (serum creatinine \<1.4mg/dL).~6. Adequate liver function (bilirubin \< 1.5 times ULN).~   * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \< 5 times the upper limit of normal in case of liver metastases.~  * ALT or AST \< 2.5 times the ULN in absence of liver metastases.~7. Ability to understand and complete written informed consent.~8. Mentally, physically, and geographically able to undergo treatment and follow up.~Exclusion Criteria:~1. Patients diabetes mellitus. (Patients with only a history of gestational diabetes will be allowed to be included in the study.)~2. Metformin use in the last 6 months.~3. A known hypersensitivity to metformin.~4. A history of metabolic acidosis, including ketoacidosis or increased risk of lactic acidosis.~5. Pregnancy or Lactation.~6. Patients who have any severe and/or uncontrolled medical conditions.~7. Patients with a history of renal disease.~8. Patients with other known active malignancy (excluding adequately treated basal cell / squamous cell skin cancer, in situ cancer, or other cancer for which the patient has been disease free for 2 years).~9. Patients receiving any other investigational agents.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).